Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment

Bevacizumab is a standard drug for metastatic colorectal cancer (mCRC) in combination with cytotoxic chemotherapy. However, inter-individual pharmacokinetic variability was observed for bevacizumab and an exposure-response relationship for efficacy was described for bevacizumab in mCRC patients treated with 1st-line bevacizumab-based chemotherapy.

NCT Number	NCT06642844
Lead Sponsor	University Hospital, Tours Collaborators: CHU DE BESANCON, Gustave Roussy, Cancer Campus, Grand Paris, University Hospital, Clermont-Ferrand, CHU de Reims, CHU de Brest, Pitié-Salpêtrière Hospital, University Hospital, Rouen, Poitiers University Hospital, Institut Paoli-Calmettes, Rennes University Hospital, University Hospital, Toulouse, AP-HP, Hôpital Saint-Louis, HCL Hôpital Edouard Hériot, Centre Hospitalier Universitaire Dijon, Nantes University Hospital, Centre Hospitalier Universitaire, Amiens, Hôpital Privé Jean Mermoz, AP-HP, Hôpital Henri Mondor, Hopital Paul Brousse, CHG de St-Malo, Polyclinique de Blois, University Hospital, Caen, Central Hospital, Nancy, France
Conditions	Unresectable Metastatic Colorectal Cancer
Enrollment	244 participants
Start Date	2025-03-04
Primary Completion	2028-03-04 (estimated)
Study Completion	2029-03-04 (estimated)
Updated on ClinicalTrials.gov	2026-06-16